Giapreza FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved December 21, 2017)
Brand name: Giapreza
Generic name: angiotensin II
Dosage form: Injection
Previous Name: LJPC-501
Company: Innoviva Specialty Therapeutics
Treatment for: Hypotension, Shock
Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.
Development timeline for Giapreza
| Date | Article |
|---|---|
| Dec 21, 2017 | Approval FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure |
| Aug 28, 2017 | La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501 |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.